Top Markets
Coin of the day
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.

AIM Vaccine Co., Ltd.

6660
Classement en actions #16632
Operating within the People's Republic of China, AIM Vaccine Co., Ltd.... Operating within the People's Republic of China, AIM Vaccine Co., Ltd. specializes in the entire lifecycle of human vaccine products, encompassing their discovery, production, and market introduction. Among its current developments, the company is advancing Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA vaccine candidates for COVID-19, both currently undergoing Phase III clinical trials. Its comprehensive portfolio also features vaccines targeting a range of other conditions, such as an EV71-CA16 Bivalent vaccine for Hand, Foot, and Mouth Disease (HFMD), and both Conjugate and Polysaccharide versions for pneumococcal disease. Further offerings include a Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine, various Diphtheria, Tetanus, and Pertussis (DTP) formulations (including DTP combined with Haemophilus Influenzae type B, acellular pertussis, and absorbed tetanus), a Haemophilus Influenzae Type B (Hib) vaccine, and both traditional freeze-dried and innovative mRNA human rabies vaccines. Beyond these, AIM Vaccine is actively developing several other vaccines, including 2- and 3-valent Human Papillomavirus (HPV) vaccines, a Tetravalent Meningococcal Conjugate vaccine, a Tetravalent Influenza vaccine, mRNA-based vaccines for Shingles/Herpes Zoster and Respiratory Syncytial Virus (RSV), a live attenuated parotitis vaccine, and an ACYW135 meningococcal polysaccharide vaccine. Established in 2011 and headquartered in Beijing, PRC, the company adopted its current name, AIM Vaccine Co., Ltd., in September 2020, having previously operated as Beijing AIM Biological Vaccine Technology Group Co., Ltd.
Prix de l'action
$0.22834832
Capitalisation boursière
$279.60M
Changement (1 jour)
4.08%
Changement (1 an)
-64.70%
Pays
CN
Échange AIM Vaccine Co., Ltd. (6660)

Catégorie

Le prix 6660 avec la capitalisation boursière de B
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.
6660
$0.22834832
Capitalisation boursière de AIM Vaccine Co., Ltd.(6660)
Capitalisation boursière: $279.60M
En September 2026, AIM Vaccine Co., Ltd. a une capitalisation boursière de $279.60M. Cela fait de AIM Vaccine Co., Ltd. la 16632nd entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de AIM Vaccine Co., Ltd. du 2022 au 2026
6660 par rapport au top 5 des plus populaires stocks
Prix pour 6660 L’actif B La capitalisation boursière de B Résultats
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.
$4,295.50 $279.60M
$5.260T +1,881,017.45%
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.
$3,902.61 $279.60M
$4.779T +1,708,958.17%
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.
$3,280.45 $279.60M
$4.017T +1,436,501.23%
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.
$3,037.54 $279.60M
$3.719T +1,330,123.83%
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.
$2,233.04 $279.60M
$2.734T +977,810.22%